| P50 | author | Yao Zhu | Q80682572 |
| P2093 | author name string | Peipei Zhang | |
| | Xiaolin Lu | |
| | Dingwei Ye | |
| P2860 | cites work | Evaluation of Dual-Timepoint 18F-FDG PET/CT Imaging for Lymph Node Staging in Vulvar Cancer. | Q50621651 |
| | Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease. | Q51707520 |
| | Bladder cancer. | Q52810295 |
| | Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease. | Q53180577 |
| | HER2 oncogene amplification in extramammary Paget's disease. | Q53861060 |
| | Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast. | Q54284515 |
| | Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. | Q54453342 |
| | Extramammary Paget disease - clinical appearance, pathogenesis, management | Q56594205 |
| | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 |
| | HER-2/neu expression in Paget disease of the vulva and the female breast | Q80878239 |
| | Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein | Q81537293 |
| | Usefulness of sentinel lymph node biopsy for extramammary Paget disease | Q83991299 |
| | HER-2/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy | Q84056149 |
| | Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy | Q84430176 |
| | Immunohistochemical and fluorescence in situ hybridization studies on noninvasive and invasive extramammary Paget's disease | Q87355495 |
| | Primary invasive carcinoma associated with penoscrotal extramammary Paget's disease: a clinicopathological analysis of 56 cases | Q87679150 |
| | Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. | Q27851468 |
| | Activating HER2 mutations in HER2 gene amplification negative breast cancer | Q27851987 |
| | Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature. | Q27853133 |
| | p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease | Q31098644 |
| | A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy | Q35563831 |
| | Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease | Q35812141 |
| | Extramammary Paget's Disease in Two Brothers | Q35944234 |
| | Clinical and pathological characteristics of extramammary Paget's disease: report of 246 Chinese male patients | Q36375388 |
| | ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. | Q36962935 |
| | Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification | Q37045824 |
| | HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review | Q37077883 |
| | An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models | Q37690880 |
| | Extra-mammary Paget's disease of the perianal region: a review of the literature emphasizing the operative management technique. | Q37795321 |
| | Extramammary Paget disease - clinical appearance, pathogenesis, management | Q37825971 |
| | H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 | Q39687743 |
| | Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease. | Q40279396 |
| | HER2 gene copy number and breast cancer-specific survival | Q40714642 |
| | Dramatic Clinical Response of Relapsed Metastatic Extramammary Paget's Disease to Trastuzumab Monotherapy | Q41809775 |
| | Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget's disease | Q42170233 |
| | Immunohistochemical study of HER2 and TUBB3 proteins in extramammary Paget disease | Q43036839 |
| | Bladder cancer: epidemiology, staging and grading, and diagnosis. | Q45247416 |
| | Variable patterns of positron emission tomography in the assessment of patients with extramammary Paget's disease | Q45251646 |
| | HER-2/NEU overexpression in vulvar Paget disease: the Yale experience. | Q45928424 |
| | F-18 FDG PET/CT imaging of extramammary Paget disease of the perianal region | Q46771121 |
| | Evaluation of positron emission tomography imaging to detect lymph node metastases in patients with extramammary Paget's disease | Q48125018 |
| | Sentinel lymph node biopsy in patients with extramammary Paget's disease. | Q50488004 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | extramammary Paget's disease | Q3077016 |
| | targeted therapy | Q492646 |
| | biomarker | Q864574 |
| P304 | page(s) | 2677-2686 | |
| P577 | publication date | 2019-01-14 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease | |
| P478 | volume | 17 | |